Advances in Adjuvant and Neoadjuvant Therapy for Melanoma.
Hematol Oncol Clin North Am
; 38(5): 953-971, 2024 Oct.
Article
em En
| MEDLINE
| ID: mdl-39060118
ABSTRACT
Melanoma remains one of the most common cancers diagnosed in the United States, yet there have been substantial advancements in the treatment of resectable disease. Adjuvant therapy with immune checkpoint blockade (ICB) and targeted therapy with BRAF/MEK inhibitors (BRAF/MEKi) have now become standard of care for resectable stage IIIB-IV melanoma. In this article, the authors discuss recent scientific developments pertinent to the treatment of resectable melanoma including ICB, targeted therapy with BRAF/MEKi, oncolytic viruses, tumor-infiltrating lymphocyte therapy, and cancer vaccines.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Terapia Neoadjuvante
/
Inibidores de Checkpoint Imunológico
/
Melanoma
Limite:
Humans
Idioma:
En
Revista:
Hematol Oncol Clin North Am
Ano de publicação:
2024
Tipo de documento:
Article